Cargando…

Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin

Levonadifloxacin (intravenous) and its oral prodrug alalevonadifloxacin are broad-spectrum antibacterial agents developed for the treatment of difficult-to-treat infections caused by multidrug-resistant Gram-positive bacteria, especially methicillin-resistant Staphylococcus aureus, atypical bacteria...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Yatin, Mishra, K. C., Paliwal, Yashesh, Rangappa, Pradeep, Sinha, Sharmili, Bhapkar, Sandeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922174/
https://www.ncbi.nlm.nih.gov/pubmed/36785544
http://dx.doi.org/10.1155/2022/2668199
_version_ 1784887485596172288
author Mehta, Yatin
Mishra, K. C.
Paliwal, Yashesh
Rangappa, Pradeep
Sinha, Sharmili
Bhapkar, Sandeep
author_facet Mehta, Yatin
Mishra, K. C.
Paliwal, Yashesh
Rangappa, Pradeep
Sinha, Sharmili
Bhapkar, Sandeep
author_sort Mehta, Yatin
collection PubMed
description Levonadifloxacin (intravenous) and its oral prodrug alalevonadifloxacin are broad-spectrum antibacterial agents developed for the treatment of difficult-to-treat infections caused by multidrug-resistant Gram-positive bacteria, especially methicillin-resistant Staphylococcus aureus, atypical bacteria, anaerobic bacteria, and biodefence pathogens as well as Gram-negative bacteria. Levonadifloxacin has a well-defined mechanism of action involving a strong affinity for DNA gyrase as well as topoisomerase IV. Alalevonadifloxacin with widely differing solubility and oral bioavailability has pharmacokinetic profile identical to levonadifloxacin. Unlike existing MRSA drugs such as vancomycin and linezolid, which cause unfavorable side effects like nephrotoxicity, bone-marrow toxicity, and muscle toxicity, levonadifloxacin/alalevonadifloxacin has demonstrated superior safety and tolerability features with no serious adverse events. Levonadifloxacin/alalevonadifloxacin could be a useful weapon in the battle against infections caused by resistant microorganisms and could be a preferred antibiotic of choice for empirical therapy in the future.
format Online
Article
Text
id pubmed-9922174
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-99221742023-02-12 Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin Mehta, Yatin Mishra, K. C. Paliwal, Yashesh Rangappa, Pradeep Sinha, Sharmili Bhapkar, Sandeep Crit Care Res Pract Review Article Levonadifloxacin (intravenous) and its oral prodrug alalevonadifloxacin are broad-spectrum antibacterial agents developed for the treatment of difficult-to-treat infections caused by multidrug-resistant Gram-positive bacteria, especially methicillin-resistant Staphylococcus aureus, atypical bacteria, anaerobic bacteria, and biodefence pathogens as well as Gram-negative bacteria. Levonadifloxacin has a well-defined mechanism of action involving a strong affinity for DNA gyrase as well as topoisomerase IV. Alalevonadifloxacin with widely differing solubility and oral bioavailability has pharmacokinetic profile identical to levonadifloxacin. Unlike existing MRSA drugs such as vancomycin and linezolid, which cause unfavorable side effects like nephrotoxicity, bone-marrow toxicity, and muscle toxicity, levonadifloxacin/alalevonadifloxacin has demonstrated superior safety and tolerability features with no serious adverse events. Levonadifloxacin/alalevonadifloxacin could be a useful weapon in the battle against infections caused by resistant microorganisms and could be a preferred antibiotic of choice for empirical therapy in the future. Hindawi 2022-09-09 /pmc/articles/PMC9922174/ /pubmed/36785544 http://dx.doi.org/10.1155/2022/2668199 Text en Copyright © 2022 Yatin Mehta et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Mehta, Yatin
Mishra, K. C.
Paliwal, Yashesh
Rangappa, Pradeep
Sinha, Sharmili
Bhapkar, Sandeep
Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin
title Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin
title_full Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin
title_fullStr Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin
title_full_unstemmed Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin
title_short Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin
title_sort meeting the unmet need in the management of mdr gram-positive infections with oral bactericidal agent levonadifloxacin
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922174/
https://www.ncbi.nlm.nih.gov/pubmed/36785544
http://dx.doi.org/10.1155/2022/2668199
work_keys_str_mv AT mehtayatin meetingtheunmetneedinthemanagementofmdrgrampositiveinfectionswithoralbactericidalagentlevonadifloxacin
AT mishrakc meetingtheunmetneedinthemanagementofmdrgrampositiveinfectionswithoralbactericidalagentlevonadifloxacin
AT paliwalyashesh meetingtheunmetneedinthemanagementofmdrgrampositiveinfectionswithoralbactericidalagentlevonadifloxacin
AT rangappapradeep meetingtheunmetneedinthemanagementofmdrgrampositiveinfectionswithoralbactericidalagentlevonadifloxacin
AT sinhasharmili meetingtheunmetneedinthemanagementofmdrgrampositiveinfectionswithoralbactericidalagentlevonadifloxacin
AT bhapkarsandeep meetingtheunmetneedinthemanagementofmdrgrampositiveinfectionswithoralbactericidalagentlevonadifloxacin